Close Menu

Eli Lilly

Under the Phenotypic Drug Discovery program, researchers from academia or biotech submit candidate compounds in specific therapeutic areas for Lilly to evaluate and profile. Participating organizations retain full IP rights to the compounds, but Lilly receives first rights to negotiate a broader collaboration or licensing agreement.

Nanosphere will develop PGx assays to run on its Verigene SP system.

SeqWright CEO Fei Lu said this week that Lilly is one of an increasing number of pharma customers that have specifically requested sequence capture and sequencing services from the firm.

Under the collaboration, SeqWright, a sequencing service provider based in Houston, will use NimbleGen's sequence capture technology and 454's sequencing platform to selectively enrich and sequence approximately 40 megabases of the human genome.

SeqWright will use the sequencing and sequence capture technologies to identify disease variants.

An Alexandria official would not discuss whether the deal would hasten a decision to begin the project's second phase, which has been delayed due to the ongoing economic upheaval.

Sirius will work with a system of 37 hospitals to test biomarkers for severe sepsis drug response.

The agreement is an extension of an existing deal between the two companies for access to Cerep's GPCR screening portfolio.

Findings from the initiative "could ultimately form the basis for collaboration or licensing agreements between Lilly and external institutions," the company said.

Linguamatics plans this year to continue building a customer base among large pharmaceutical firms, while Bioalma is eyeing the academic market to help drive growth in 2009.

Pages

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

Politico reports President Donald Trump has signed the $2 trillion coronavirus relief package.

A new analysis finds that peer review improves the quality of preprints just a little bit, according to ScienceInsider.

In PLOS this week: epigenetic drug triggers anti-viral activity, viral diversity among individuals with HIV experiencing virological failure, and more.